Equillium Inc. (NASDAQ: EQ)
$0.94
+0.0468 ( +5.26% ) 177.8K
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Market Data
Open
$0.94
Previous close
$0.89
Volume
177.8K
Market cap
$32.07M
Day range
$0.83 - $0.94
52 week range
$0.45 - $3.25
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
ars | Annual reports | 1 | Apr 11, 2024 |
def | Proxies and info statements | 14 | Apr 11, 2024 |
8-k | 8K-related | 13 | Apr 01, 2024 |
pre | Proxies and info statements | 13 | Apr 01, 2024 |
10-k | Annual reports | 96 | Mar 25, 2024 |
8-k | 8K-related | 15 | Mar 25, 2024 |
8-k | 8K-related | 15 | Mar 08, 2024 |
3 | Insider transactions | 2 | Mar 08, 2024 |
8-k | 8K-related | 16 | Feb 23, 2024 |
8-k | 8K-related | 14 | Feb 22, 2024 |